)

Regeneron Pharmaceuticals (REGN) investor relations material
Regeneron Pharmaceuticals Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Commercial performance and product updates
EYLEA HD saw strong sequential demand growth in Q1 and Q2, driven by effective commercial execution and education efforts targeting both physicians and patients.
Key upcoming regulatory milestones include a PDUFA date in late October for the prefilled syringe and another in late November for RVO and Q4 dosing sBLA, with confidence in timely resolution of manufacturing issues.
Biosimilar competition for EYLEA 2mg has led to gradual market uptake, with additional entrants expected in late 2026, potentially increasing pricing pressure.
DUPIXENT continues to perform strongly across eight approved indications, with growth driven by established and new launches, particularly in COPD.
Investments in COPD launch leverage existing pulmonary field teams, with high early adoption among top pulmonologists and a focus on both physician and patient education.
Pipeline and R&D strategy
Strategic ambition is to develop a basket of opportunities, including longer-acting DUPIXENTs and novel inflammatory targets, to sustain growth beyond DUPIXENT’s exclusivity in 2031.
Oncology pipeline features recent approvals for bispecifics, with early Linezyth launch feedback positive and plans to expand into earlier lines and precursor conditions.
Upcoming studies include combinations in second line plus myeloma and trials in newly diagnosed and smoldering myeloma, with promising early data in precursor conditions.
LAG-3 combination trials in melanoma aim to outperform current standards, with key readouts expected and a head-to-head study against Opdualag maturing by 2027.
Complement and Factor XI programs show promise in MG, PNH, geographic atrophy, and anticoagulation, with multiple phase 2 and 3 studies underway and initial data expected in 2027.
Obesity and metabolic programs
Muscle-sparing agents combined with GLP-1 therapies demonstrated significant preservation of lean mass during weight loss, with ongoing studies to assess long-term effects.
Licensed GLP-1/GIP asset olorepatide will be developed as a monotherapy and in combination, with a phase 3 program planned for next year.
Next Regeneron Pharmaceuticals earnings date

Next Regeneron Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage